Angiotensin Receptor Blockers

ApprovedSmall molecule

Angiotensin Receptor Blockers is one of 126 small molecule programs targeting Mitral regurgitation. It is currently in Approved.

Indications

Total Trials

Active Trials

125

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitral RegurgitationActive, not recruiting

Aortic StenosisActive, not recruiting

PneumoniaActive, not recruiting

COVID-19Active, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

Aortic StenosisApproved

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

COVID-19Approved

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Angiotensin Receptor Blockers

TThe George Institute

Approved

3 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Biaxin

AbbVie

Preclinical

2 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Other Tkis

Bayer

Preclinical

1 10

Opaganib

RRedHill Biopharma Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Not yet recruiting

Pneumonia

NCT07262710

Q4 2026

Phase 3Recruiting

Statins

NCT03770702

Q1 2027

Post-ApprovalRecruiting

Aortic Stenosis

NCT04913870

Q1 2028

Phase 3Recruiting

Pneumonia

NCT02735707

Clinical

Trials by Indication[1]

Pneumonia3 trials

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study

Not yet recruiting·—··NCT07262710·13,656 enrolled

Drug to Prevent Pneumonia in the Tube Fed

Terminated·—·Phase 4·NCT02358642·93 enrolled

COVID-193 trials

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

Completed·TThe George Institute·Phase 4·NCT04394117·787 enrolled

The COVID-RASi Trial (COVID-19)

Completed·OOttawa Heart Institute Research Corporation·Phase 3·NCT04591210·372 enrolled

ARB, ACEi, DRi Effects on COVID-19 Course Disease

Completed·MMedical Practice Prof D. Ivanov··NCT04364984·112 enrolled

Statins1 trial

Statins and ARBs on Rheumatoid Activity

Recruiting·SSherief Abd-Elsalam·Phase 3·NCT03770702·45 enrolled

Mitral regurgitation1 trial

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

Completed·—·N/A·NCT00224809·250 enrolled

Hypertensive1 trial

Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients

Completed·—·Phase 4·NCT00135551·3,501 enrolled

6 more indications

Not yet recruiting·UUniversity of Southern California·Phase 2·NCT07447206·10 enrolled

Chronic Kidney Disease1 trial

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT00874432·43 enrolled

Angiotensin Converting Enzyme1 trial

Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children

Completed·VVanderbilt University Medical Center·N/A·NCT00848250·21 enrolled

ALS1 trial

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Terminated·—·Phase 4·NCT02788656·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Angiotensin Receptor Blockers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Angiotensin Receptor Blockers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Angiotensin Receptor Blockers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The George Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe George Institute

Angiotensin Receptor Blockers

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q1 2028

Trials by Indication[1]

Pneumonia3 trials

COVID-193 trials

Statins1 trial

Mitral regurgitation1 trial

Hypertensive1 trial

Renal Transplant Recipients1 trial

Aortic Stenosis1 trial

Trial1 trial

Chronic Kidney Disease1 trial

Angiotensin Converting Enzyme1 trial

ALS1 trial

References

Drug Info

Quick Facts

Related News